A comprehensive review of hematology and
oncology topics emphasizing recent developments and updates on the
evaluation and treatment of cancer and blood disorders.
Over the
years, the field of Hematology has undergone enormous expansion in
clinical trials and basic research as well as in cutting-edge
technology.
The 1st World Congress on Controversies in Hematology (COHEM)
will function as an exclusive forum for international experts to share
and compare experiences, in order to outline the right treatment for
patients.
The concept of this Congress
stems from the fact that current congresses fail to promote true
clinical discussion between practicing physicians and researchers on
unresolved pressing issues.
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
The Society for Hematology and Stem Cells (ISEH) was established in 1950
by a group of scientists who sought to create a forum for the
presentation and discussion of pre-clinical data in experimental
hematology. ISEH continues to be dedicated to the promotion of the
scientific knowledge and clinical application of basic hematologic and
immunologic disorders through research, publications, and scientific
programs. Incorporated in 1972 in the USA, the Society has over 800
active members from 40 countries around the world. Its annual scientific
meeting attracts more than 500 participants over 4 days and, together
with its official monthly journal Experimental Hematology, provides
essential delivery of quality education, training programs, discussion
forums, as well as promotes basic research.
The preliminary proposed program:
Session 1: Clinical Application of Cytokines Session 2: Megakaryocytopoiesis Session 3: Molecular Basis of Leukemia Session 4: Developmental Hemopoiesis (in memory of Greg Johnson) Session 5: Animal Models of leukemiagenesis Session 6: Pluripotency to Blood 1 Session 7: BMTS ANZ Session Session 8: Pluripotency to Blood 2 Session 9: HSC Mobilisation
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
ISH 2010 provides an essential platform for hematologists from around the world to discuss problems with colleagues and experts and to discover the latest research, therapies and tools available in this constantly evolving field. This advanced world congress features a state-of-the-art scientific program that furthers the aims of the International Society of Hematology (ISH).
ISH 2010 provides an essential platform for hematologists from around the world to discuss problems with colleagues and experts and to discover the latest research, therapies and tools available in this constantly evolving field. This advanced world congress features a state-of-the-art scientific program that furthers the aims of the International Society of Hematology (ISH).
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
A live interactive training program for the multidisciplinary myeloma care team! Participants will work through clinical cases with regional and national myeloma experts. This CE program will address treatment strategies that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists, physician assistants, and nurse practitioners in hematology and oncology. The meeting takes place from 7:30 am – 1:00 pm. Breakfast and lunch are included and there are no fees for participation.
A live interactive training program for the
multidisciplinary myeloma care team! Participants will work through clinical cases with regional
and national myeloma experts. This CE program will address treatment strategies
that are most appropriate for myeloma patients.
This activity is for physicians, nurses, pharmacists,
physician assistants, and nurse practitioners in hematology and oncology.
The meeting takes place from 7:30 am – 1:00 pm. Breakfast and
lunch are included and there are no fees for participation.
The American Society of Hematology (ASH) welcomes you to Orlando for our 52nd annual meeting. This event offers invaluable benefits, including:
The opportunity to grow professionally: Hematology is a constantly changing field, and ASH’s Education and Scientific Program can help you stay up-to-date on the latest research, therapies, and tools you need to succeed.
The meeting offers many networking events that will allow you to connect with colleagues and interact with leaders in the field to learn and share your ideas.
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) will function as an exclusive forum for international experts to share and compare experiences, in order to outline the right treatment for patients. This innovative Congress is unique in its explicit focus on resolving controversies in best clinical care of patients.
The Annual Congress of the European Hematology Association invites you to come and experience the next step
of this annual European event.
As in previous years the Scientific Program Committee (SPC), its
Advisory Board and all other committees involved have done their utmost
to create a program that promotes excellence in all fields of
hematology. Its Plenary Sessions are designed to be of interest to all
specialties with key note speakers providing interesting presentations.
The highly valued Education Sessions and Hematology-in-Focus offer a
wide range of topics discussed on many levels. Joint symposia will be
organized with the American Society of Hematology, the European School
of Haematology and a new collaboration with the Japanese Society of
Hematology has resulted in a special symposium.
Another highlight in the organization of the Congress is the
well-established Molecular Hemopoiesis Workshop, preceded in the
morning with the brand new Laboratory Hematology Workshop. This new
workshop will bring an extended focus on diagnostics into the program.
Furthermore, the lunch debates are in heated preparation at the moment,
already causing a rumor within the SPC. The Meet-the-Experts will offer
a chance to discuss and put your questions before an authority in
hematology and the Scientific Working Groups are designing their
sessions to show also their valued scientific work.
The International Society of Blood Transfusion (ISBT) is a
scientific
society, founded in 1935 and joining over 1000 professionals
involved in
blood transfusion and transfusion medicine from more than 100
countries.
The International Society of Blood Transfusion (ISBT) is a
scientific
society, founded in 1935 and joining over 1000 professionals
involved in
blood transfusion and transfusion medicine from more than 100
countries.
The Annual Congress of the European Hematology Association invites you to come and experience the next step
of this annual European event.
As in previous years the Scientific Program Committee (SPC), its
Advisory Board and all other committees involved have done their utmost
to create a program that promotes excellence in all fields of
hematology. Its Plenary Sessions are designed to be of interest to all
specialties with key note speakers providing interesting presentations.
The highly valued Education Sessions and Hematology-in-Focus offer a
wide range of topics discussed on many levels. Joint symposia will be
organized with the American Society of Hematology, the European School
of Haematology and a new collaboration with the Japanese Society of
Hematology has resulted in a special symposium.
Another highlight in the organization of the Congress is the
well-established Molecular Hemopoiesis Workshop, preceded in the
morning with the brand new Laboratory Hematology Workshop. This new
workshop will bring an extended focus on diagnostics into the program.
Furthermore, the lunch debates are in heated preparation at the moment,
already causing a rumor within the SPC. The Meet-the-Experts will offer
a chance to discuss and put your questions before an authority in
hematology and the Scientific Working Groups are designing their
sessions to show also their valued scientific work.
The International Society of Blood Transfusion (ISBT) is a
scientific
society, founded in 1935 and joining over 1000 professionals
involved in
blood transfusion and transfusion medicine from more than 100
countries.
The fifth official Highlights of ASH® in Toronto, Ontario, will feature leading hematology experts who will present unbiased analysis of the annual meeting abstracts and sessions, evolving therapies, and the latest treatment options and their clinical applications.
The program format is designed to allow practitioners, fellows, academicians, and allied health professionals to discuss some of the most rapidly evolving developments in the field with experts as well as colleagues. The limited attendance, daily panel discussions, and the “Breakfast with the Experts,” will provide numerous opportunities for attendees to discuss real patient cases with leaders in the field, gain knowledge that can impact patient care strategies, and network with colleagues.
This educational activity is specifically designed for
hematologists/oncologists, internists, nurses, pharmacists, and other
healthcare professionals with an interest and/or involvement in
hematologic malignancies.
Objectives
After successful completion of this course, attendees should be able to:
Discuss the most clinically relevant data presented at the 51st Annual Hematology Meeting
Analyze emerging data on multiple hematologic malignancies and benign abnormalities in order to improve patient outcomes
Explain
the limitations and benefits of new and emerging therapies for the
treatment of patients with benign and malignant hematologic conditions
Incorporate emerging data into the clinical management of patients with benign and malignant hematologic conditions
Discuss ways in which current clinical practice should be modified based on the latest advances in hematology
The fifth official Highlights of ASH® will feature leading hematology experts who will present
unbiased analysis of the annual meeting abstracts and sessions,
evolving therapies, and the latest treatment options and their clinical
applications.
Program
Topics
Acute Myeloid
Leukemia: New Therapeutic Targets
Myelodysplastic
Syndromes
Chronic Myeloid Leukemia
and other Myeloproliferative diseases
Chronic
Lymphocytic Leuekemia: Novel Therapies
B-Cell Lymphomas:
New Molecular Targets
Hodgkin Lymphoma:
Clinical Challenges and New Approaches
Pathophysiology
of Hemorrhage and thrombosis
Novel Treatments
for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura
This educational activity is specifically designed for
hematologists/oncologists, internists, nurses, pharmacists, and other
healthcare professionals with an interest and/or involvement in
hematologic malignancies.
Objectives
After successful completion of this course, attendees should be able to:
Discuss the most clinically relevant data presented at the 51st Annual Hematology Meeting
Analyze emerging data on multiple hematologic malignancies and benign abnormalities in order to improve patient outcomes
Explain
the limitations and benefits of new and emerging therapies for the
treatment of patients with benign and malignant hematologic conditions
Incorporate emerging data into the clinical management of patients with benign and malignant hematologic conditions
Discuss ways in which current clinical practice should be modified based on the latest advances in hematology
This unique series of four live, one-day meetings will provide expert reviews of the most meaningful and practice-changing data in the field of hematologic malignancies presented at ASH and other major society meetings held throughout 2009. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes.”
The fifth official Highlights of ASH® will feature leading hematology experts who will present
unbiased analysis of the annual meeting abstracts and sessions,
evolving therapies, and the latest treatment options and their clinical
applications.
Program
Topics
Acute Myeloid
Leukemia: New Therapeutic Targets
Myelodysplastic
Syndromes
Chronic Myeloid Leukemia
and other Myeloproliferative diseases
Chronic
Lymphocytic Leuekemia: Novel Therapies
B-Cell Lymphomas:
New Molecular Targets
Hodgkin Lymphoma:
Clinical Challenges and New Approaches
Pathophysiology
of Hemorrhage and thrombosis
Novel Treatments
for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura
The fifth official Highlights of ASH® will feature leading hematology experts who will present
unbiased analysis of the annual meeting abstracts and sessions,
evolving therapies, and the latest treatment options and their clinical
applications.
Program
Topics
Acute Myeloid
Leukemia: New Therapeutic Targets
Myelodysplastic
Syndromes
Chronic Myeloid Leukemia
and other Myeloproliferative diseases
Chronic
Lymphocytic Leuekemia: Novel Therapies
B-Cell Lymphomas:
New Molecular Targets
Hodgkin Lymphoma:
Clinical Challenges and New Approaches
Pathophysiology
of Hemorrhage and thrombosis
Novel Treatments
for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura
This educational activity is specifically designed for
hematologists/oncologists, internists, nurses, pharmacists, and other
healthcare professionals with an interest and/or involvement in
hematologic malignancies.
Objectives
After successful completion of this course, attendees should be able to:
Discuss the most clinically relevant data presented at the 51st Annual Hematology Meeting
Analyze emerging data on multiple hematologic malignancies and benign abnormalities in order to improve patient outcomes
Explain
the limitations and benefits of new and emerging therapies for the
treatment of patients with benign and malignant hematologic conditions
Incorporate emerging data into the clinical management of patients with benign and malignant hematologic conditions
Discuss ways in which current clinical practice should be modified based on the latest advances in hematology
This educational activity is specifically designed for
hematologists/oncologists, internists, nurses, pharmacists, and other
healthcare professionals with an interest and/or involvement in
hematologic malignancies.
Objectives
After successful completion of this course, attendees should be able to:
Discuss the most clinically relevant data presented at the 51st Annual Hematology Meeting
Analyze emerging data on multiple hematologic malignancies and benign abnormalities in order to improve patient outcomes
Explain
the limitations and benefits of new and emerging therapies for the
treatment of patients with benign and malignant hematologic conditions
Incorporate emerging data into the clinical management of patients with benign and malignant hematologic conditions
Discuss ways in which current clinical practice should be modified based on the latest advances in hematology
This one-day educational program will provide
hematology and oncology clinicians, nurse practitioners, and physician
assistants with an overview of the most recent advances in the
treatment of various hematologic malignancies, based on abstracts
presented at the December 2009 annual meeting of the American Society
of Hematology (ASH). Invited speakers choose exciting and relevant
abstracts presented at the ASH meeting and discuss their clinical
relevance to the hematology/oncology practice.
The fifth official Highlights of ASH® will feature leading hematology experts who will present
unbiased analysis of the annual meeting abstracts and sessions,
evolving therapies, and the latest treatment options and their clinical
applications.
Program
Topics
Acute Myeloid
Leukemia: New Therapeutic Targets
Myelodysplastic
Syndromes
Chronic Myeloid Leukemia
and other Myeloproliferative diseases
Chronic
Lymphocytic Leuekemia: Novel Therapies
B-Cell Lymphomas:
New Molecular Targets
Hodgkin Lymphoma:
Clinical Challenges and New Approaches
Pathophysiology
of Hemorrhage and thrombosis
Novel Treatments
for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura
The fifth official Highlights of ASH® will feature leading hematology experts who will present
unbiased analysis of the annual meeting abstracts and sessions,
evolving therapies, and the latest treatment options and their clinical
applications.
Program
Topics
Acute Myeloid
Leukemia: New Therapeutic Targets
Myelodysplastic
Syndromes
Chronic Myeloid Leukemia
and other Myeloproliferative diseases
Chronic
Lymphocytic Leuekemia: Novel Therapies
B-Cell Lymphomas:
New Molecular Targets
Hodgkin Lymphoma:
Clinical Challenges and New Approaches
Pathophysiology
of Hemorrhage and thrombosis
Novel Treatments
for Relapsed/Refractory Chronic Idiopathic Thrombocytopenic Purpura
This unique series of four live, one-day meetings will provide expert
reviews of the most meaningful and practice-changing data in the field
of hematologic malignancies presented at ASH and other major society
meetings held throughout 2009. In addition to didactic lectures, the
format of the meeting also includes interactive “The Smartest
Oncologist/Hematologist Quizzes.”
This unique series of four live, one-day meetings will provide expert
reviews of the most meaningful and practice-changing data in the field
of hematologic malignancies presented at ASH and other major society
meetings held throughout 2009. In addition to didactic lectures, the
format of the meeting also includes interactive “The Smartest
Oncologist/Hematologist Quizzes.”
This unique series of four live, one-day meetings will provide expert
reviews of the most meaningful and practice-changing data in the field
of hematologic malignancies presented at ASH and other major society
meetings held throughout 2009. In addition to didactic lectures, the
format of the meeting also includes interactive “The Smartest
Oncologist/Hematologist Quizzes.”
Dear members of the GTH and NVTH, dear colleagues, physicians, investigators and students in the field of haemostaseology,
With great pleasure we, on behalf of the organising committee and our societies, invite you to attend the 54th Congress of the „Gesellschaft für Thrombose- und Hämostaseforschung“ (GTH) which is also a meeting of “Nederlandse Vereniging voor Trombose en Hemostase”
(NVTH). For the first time the "GTH 2010" is the joint meeting of these
two sister societies. Our joint meeting scheduled for February 24 -27,
2010, will take place in the Franconian capital of Nürnberg which is
near to the university town of Würzburg. Nearly 160 years ago, in
1849/1850, five highly talented professors of Würzburg University
founded the “Societas Physico-Medica” which initiated an enduring
spirit of interdisciplinary collaboration between basic and clinical
scientists. One member of this academic society, Röntgen, later
discovered the X-rays. Another founding member (see below), Rudolf
Virchow, not only established the concept of molecular and cellular
pathology but was one of the founding fathers of the field thrombosis
and hemostasis. Other members of this academic society in Würzburg
included a biochemist, a pharmacologist, a clinical chemist and a
clinician (see below). Such interdisciplinary collaboration is also the
true hallmark of the field of thrombosis and hemostasis which nowadays
covers many fields of basic and clinical sciences. In the tradition of
this interdisciplinary collaboration, and in the tradition of former
GTH and NVTH meetings, we now plan the first joint meeting of the GTH
and NVTH for 2010. We truly hope that our meeting and its program with
plenary lectures, educational sessions, scientific symposia, free
communications and posters will attract many of our GTH / NVTH members
but also scientists, clinicians and students from other neighbouring
European countries. Although facilities in Würzburg are unfortunately
too small to accommodate such a prominent meeting, we are very pleased
to organize this congress in Nürnberg which offers a wide spectrum of
historical, modern and cosmopolitan sights and opportunities. We are
also optimistic that Virchow’s spirit of interdisciplinary interaction
can be transfered from the lower Franconian town Würzburg to the
Franconian-Bavarian metropolis Nürnberg. With our congress motto “Basic
and clinical research for our patients of all ages and in all
situations” and our envisioned program, we hope to stimulate both
academic and social interactions.
This educational activity is specifically designed for
hematologists, medical oncologists, transplant oncologists, oncology
fellows, oncology nurses, internists, and other physicians,
physicians-in-training, and healthcare professionals involved in and/or
interested in lymphoma, myeloma, related plasma cell disorders, and in
the special session of 2010, acute lymphoblastic leukemia.
Educational Objectives
Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and related diseases
Discuss
the role of the microenvironment in the development and disease
progression of chronic lymphocytic leukemia and follicular lymphoma
Evaluate how the disease risk and age of a patient determines optimal management and the course of therapy for lymphoma
Describe
the biology, management, and current treatment options of myeloma and
lymphoma for front-line, salvage, and maintenance therapy, as well as
therapeutic strategies to overcome relapsed/refractory disease
Evaluate
the feasibility of chemotherapy, radioimmunotherapy, targeted therapy,
and transplantation as treatment options for various stages of indolent
lymphoma
Debate whether autologous or allogeneic stem cell transplantation is appropriate for management of mantle cell lymphoma
Employ current and novel strategies to improve diagnosis and treatment outcomes in aggressive non-Hodgkin’s lymphomas
Determine whether specific subtypes of aggressive NHL should be treated
in the same manner
Positively
impact patient outcomes by assimilating diagnostic, prognostic, and
molecular approaches toward optimal stratification for current and
novel treatment options in acute lymphoblastic leukemia.
Since 1994 PPTA’s Congresses have provided valuable insights into the issues affecting the plasma protein industry.
IPPC has been the primary international congress for all
stakeholders of plasma protein therapies. Building on the experience
and success of the past but with a clear eye to the future, the IPPC
2010 offers delegates a unique, two-day programme with speakers of the
highest calibre, representing institutions and organizations that
provide leadership and direction in several important areas.
Sessions will feature topics such as clinical developments, patient
access, self-sufficiency, regulatory considerations, plasma collection,
health policy and much more. There will be ample time for discussion
and questions after the presentations and during the cocktail buffet
reception on 16 March which will complement the full and diverse
programme.
The interests of patients and physicians are everyone’s number one
priority, be they politicians, regulators, scientists, healthcare
funding organizations and for those working in the industry. Our
intention is to create a congress for all.
This educational activity is primarily targeted
to academic and community hematologists and oncologists, and
secondarily to oncology nurses and other health care professionals
interested in the management of patients with hematologic malignancies.
Objectives
After successful completion of this course, attendees should be able to:
Identify the most effective therapeuticstrategies and novel combinations for acute leukemias, especially for the care of
elderly patients
Correctly utilize imaging techniques to ensure successful management and validate response criteria for patients with
non-Hodgkin’s lymphoma
Review traditional treatment strategies for lymphoma and decide whether emerging, updated therapies could potentially
optimize patient outcomes
Determine how the emergence of novel agents in multiple myeloma could affect the use of markers for patient risk
stratification and approaches to overcome treatment resistance
Evaluate the optimal frontline approach to multiple myeloma treatment, including the most favorable number of agents,
treatment sequencing, inclusion of novel agents, and the use of
bisphosphonates for symptom management
Determine how to effectively manage multiple myeloma patients with preexisting complications
The Platelets 2010 program will include sessions on:
• Platelet development • Platelet activation • Platelet signaling • Platelet adhesion • Platelet function testing • Genetic disorders, including functional genomics • Platelets in inflammation and atherosclerosis • Immune platelet disorders, including ITP, TTP, HIT • Platelet microparticles • Pharmacology I • Pharmacology II
Back for a second year, this meeting will offer important information on evolving therapies, as well as the latest treatment options and their clinical applications, from the 51st ASH Annual Meeting.
The 2010 program focuses on pathophysiology, diagnosis, and management of common malignant and benign hematologic disorders, including acute and chronic leukemias, lymphomas, myeloma, thrombotic disorders, myelodysplastic syndromes and myeloproliferative disorders, sickle cell anemia, transfusion medicine, hemolytic anemia and malaria, and health disparities and outcomes for patients with hematologic diseases.
The program format, including panel discussions and “Breakfast with the Experts,” will provide numerous opportunities for attendees to discuss real patient cases with leaders in the field, network with colleagues, and gain practice-changing insights.
Presentations will be delivered in English and simultaneously translated into both Portuguese and Spanish. Program materials will be available in English only. We hope you will join us at this exciting event.
The Cuban Society of Angiology and Vascular Surgery once again is
calling to the Caribbean Congress of Angiology and Vascular Surgery,
traditionally known as ANGIOCARIBE and this time together with the II
International Symposium of Diabetic Angiopathy, and the VII Meeting of
Thrombosis and Haemostasis to be held between the 17 at 21 of May, 2010
at Havana International Conference Center.
The main objective of
this event is the interchange and friendly scientific confrontation of
relevant national and international specialists devoted to peripheral
vascular diseases. Active participation of participants from abroad
will allow locals to brush up knowledge on proposed topics and at the
same time we will have the opportunity to show our scientific
achievements in the specialty.
Main Topics
Epidemiology and physiopathology of peripheral vascular diseases.
Steno-occlusive disease of the aorta and its branches.
Cerebrovascular disease.
Endovascular surgery.
Diabetic angiopathy
The diabetic foot.
Revascularization in diabetic vascular complications
Progresses in the medical and surgical treatment of veno-lymphatic diseases.
Thromboembolic disease.
Chronic venous failure.
Epidemiology and treatment of lymphedema.
Non-invasive and invasive vascular diagnosis.
Haemostasis and atherothrombosis.
Anti-thrombotic therapy.
Aging and peripheral vascular disease.
Regenerative medicine in peripheral vascular diseases.
Use of traditional and natural medicine in angiology.
Nursing action in the peripheral vascular diseases.
The Annual Congress of the European Hematology Association celebrates
its 15th anniversary from June 10-13, 2010 in Barcelona, Spain. We take
great pleasure, as Congress President and Chair of the Scientific
Program Committee, to invite you to come and experience the next step
of this annual European event with us.
As in previous years the Scientific Program Committee (SPC), its
Advisory Board and all other committees involved have done their utmost
to create a program that promotes excellence in all fields of
hematology. Its Plenary Sessions are designed to be of interest to all
specialties with key note speakers providing interesting presentations.
The highly valued Education Sessions and Hematology-in-Focus offer a
wide range of topics discussed on many levels. Joint symposia will be
organized with the American Society of Hematology, the European School
of Haematology and a new collaboration with the Japanese Society of
Hematology has resulted in a special symposium.
Another highlight in the organization of the Congress is the
well-established Molecular Hemopoiesis Workshop, preceded in the
morning with the brand new Laboratory Hematology Workshop. This new
workshop will bring an extended focus on diagnostics into the program.
Furthermore, the lunch debates are in heated preparation at the moment,
already causing a rumor within the SPC. The Meet-the-Experts will offer
a chance to discuss and put your questions before an authority in
hematology and the Scientific Working Groups are designing their
sessions to show also their valued scientific work.
The International Society of Blood Transfusion (ISBT) is a
scientific
society, founded in 1935 and joining over 1000 professionals
involved in
blood transfusion and transfusion medicine from more than 100
countries.
The congress will provide an overview of the latest developments in
transfusion medicine. Five different
streams will guide you through the congress: “from the lab to the
patient”, “cell therapy”, “quality management”,
“blood safety” and the “ISBT academy”. The last-mentioned stream will
offer young colleagues and
beginners in the field a compact overview and education opportunity as
well as state-of-the-art updates in
all facets of blood transfusion for all of us. In addition, plenary
lectures, meet-the-expert sessions, guided
poster walks, ISBT and DGTI prize lectures and satellite symposia will
take place.
The Congress provides the largest international meeting place for members of the global bleeding disorders community.
Renowned international treatment and research experts from around the world will participate in the Congress. A scientific meeting par excellence for professionals specializing in bleeding disorders, it is here that breakthroughs in hemophilia and other inherited bleeding disorders are presented.
Important
Due to possible changes in conference details, we recommend that you check with the conference
website, before making any traveling arrangements.
* Prices are for evaluation only. For accurate prices, please check with conference website.
